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Abstract
Background: Corticosteroid injection and physiotherapy are two commonly prescribed interventions for management of
lateral epicondylalgia. Corticosteroid injections are the most clinically efficacious in the short term but are associated with high
recurrence rates and delayed recovery, while physiotherapy is similar to injections at 6 weeks but with significantly lower
recurrence rates. Whilst practitioners frequently recommend combining physiotherapy and injection to overcome harmful
effects and improve outcomes, study of the benefits of this combination of treatments is lacking. Clinicians are also faced with
the paradox that the powerful anti-inflammatory corticosteroid injections work well, albeit in the short term, for a non-
inflammatory condition like lateral epicondylalgia. Surprisingly, these injections have not been rigorously tested against placebo
injections. This study primarily addresses both of these issues.
Methods: A randomised placebo-controlled clinical trial with a 2 × 2 factorial design will evaluate the clinical efficacy, cost-
effectiveness and recurrence rates of adding physiotherapy to an injection. In addition, the clinical efficacy and adverse effects of
corticosteroid injection beyond that of a placebo saline injection will be studied. 132 participants with a diagnosis of lateral
epicondylalgia will be randomly assigned by concealed allocation to one of four treatment groups – corticosteroid injection,
saline injection, corticosteroid injection with physiotherapy or saline injection with physiotherapy. Physiotherapy will comprise
8 sessions of elbow manipulation and exercise over an 8 week period. Blinded follow-up assessments will be conducted at
baseline, 4, 8, 12, 26 and 52 weeks after randomisation. The primary outcome will be a participant rating of global improvement,
from which measures of success and recurrence will be derived. Analyses will be conducted on an intention-to-treat basis using
linear mixed and logistic regression models. Healthcare costs will be collected from a societal perspective, and along with
willingness-to-pay and quality of life data will facilitate cost-effectiveness and cost-benefit analyses.
Conclusion: This trial will utilise high quality trial methodologies in accordance with CONSORT guidelines. Findings from this
study will assist in the development of evidence based practice recommendations and potentially the optimisation of resource
allocation for rehabilitating lateral epicondylalgia.
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Lateral epicondylalgia (LE), also known as 'tennis elbow',
is a musculoskeletal disorder characterised by pain over
the lateral humeral epicondyle associated with gripping or
manual tasks that require manipulation of the hand. With
an annual incidence of 1–3% within the general popula-
tion [1-5], LE is a common condition that significantly
impacts on the individual and society. Corticosteroid
injection and physiotherapy are commonly prescribed
conservative treatments for this condition. Systematic
review evidence has found corticosteroid injection pro-
vides superior short term benefits [6-9], but recent studies
suggest poorer clinical outcomes in the longer term
[10,11]. One aspect of this poorer outcome is the signifi-
cantly larger recurrence rates that have been reported fol-
lowing corticosteroid injection (72%) as compared to
physiotherapy (8%) and adoption of a wait and see policy
(10%) [10]. These late adverse outcomes are of concern to
both patients and their doctors.
Despite their regular prescription, there is a critical need to
evaluate the therapeutic and adverse effects of the corti-
costeroid injection compared to placebo. The anti-inflam-
matory mode of action of corticosteroid medication has
been questioned by evidence of an absence of classic
inflammatory mediators in this condition [12,13]. Local
injection of corticosteroid may mediate its effect through
alterations in the release of noxious chemicals or inhibi-
tion of collagen, extracellular matrix proteins and granu-
lation tissue [12,14]. However, whether these effects are
ultimately clinically beneficial or harmful in the long term
is not known.
From a clinical perspective, practitioners frequently
emphasise the importance of an active rehabilitation pro-
gram, either in isolation or in combination with injection.
In a recent study, [10] physiotherapy comprising specific
elbow manipulation combined with a progressive exercise
program was found to be as effective as the corticosteroid
injection at 6 weeks, while superior to injection at 12
weeks. When considering the overall effect over the entire
12-month follow-up period, calculated by area under the
curve, physiotherapy was superior to both corticosteroid
injection and a wait and see policy [10]. Combination of
injection with physiotherapy modalities has only been
evaluated in two small studies [15,16]. One reported that
corticosteroid injection did not provide significant
improvement in outcome when added to a program of ice
massage and physiotherapy prescribed exercises (moni-
tored at 3–4 weekly physiotherapy sessions) for patients
with LE of less than four weeks duration [16]. The authors
recommended that rehabilitation be the first line of treat-
ment. The other study found no significant effect of a pro-
gressive graduated exercise program (number of
physiotherapy sessions not specified) when added to
injection, however this study was underpowered (small
sample size), reported a high drop-out rate and did not
assess long term outcomes (only reported a 7 week follow
up) [15]. Hence, there is a high likelihood that there was
an unacceptable Type II error rate with this study.
Increasingly, the discovery of efficacious treatments needs
to be considered in the context of their costs. Research
into the cost effectiveness of corticosteroid injections,
physiotherapy or just adopting a wait and see policy for LE
demonstrated no significant cost-effectiveness differential
[17]. This project will provide economic evaluation of the
costs to relative benefits of the addition of physiotherapy
to injection. Computation of cost-effectiveness ratios will
enable a comparison of these interventions with the alter-
natives, and to compare results with others studies that
have been subjected to economic analysis. In addition,
the collection of willingness-to-pay data via a contingent
valuation study, will enable the computation of net
present value differences between the benefits and costs of
the intervention. The latter approach will determine
whether or not, in an absolute sense, the intervention is
worthwhile, on economic grounds.
In summary, the following hypotheses will be evaluated
in order to address the aims of the study: (1) Addition of
physiotherapy to an injection when compared to injec-
tion alone will improve the long term efficacy and reduce
the recurrence rates; (2) The combined corticosteroid and
local anaesthetic injection will be superior to that of saline
injection in the short term but not long term; (3a) The
benefits gained by adding physiotherapy to injection out-
weigh the costs associated with the injection alone; and
(3b) the cost-effectiveness of the combined therapy is
superior to the cost-effectiveness of injection alone.
Methods/design
A clinical trial with a 2 × 2 factorial design will be used to
study the above aims in a similar manner to a previous
study of shoulder conditions [18]. The two levels of the
two main effects of injection and physiotherapy will be
combined to constitute four treatment groups (1) corti-
costeroid injection alone, (2) saline injection alone, (3)
corticosteroid injection and physiotherapy; (4) saline
injection and physiotherapy. An overview of the study
protocol is provided in Figure 1. Ethical approval has been
obtained from the Medical Research Ethics Committee at
the University of Queensland.
Eligibility Criteria
Volunteers will be self-selected from the Brisbane and sur-
rounding regions using a comprehensive public notifica-
tion strategy (e.g., advertising and media releases). A two
stage screening process will be used, comprising a tele-
phone interview followed by a clinical examination, toPage 2 of 11
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ise the participant with testing procedures. Following a
detailed explanation of the study protocol, eligible partic-
ipants will be invited to return on a separate occasion to
complete consent documentation and baseline outcome
measurements.
Interventions
Interventions will be administered in a primary care set-
ting by one medical practitioner and one physiotherapist
(if allocated) in a manner that is considered best practice.
All practitioners will receive training to ensure treatments
are provided in accordance with the following study pro-
tocol.
Injection
A routine clinical examination will be conducted by the
treating medical practitioner prior to injection of either
(1) 1 ml Triamcinolone Acetonide (10 mg/ml) (Kenacort-
A 10) with 1 ml Lignocaine (1%) [Corticosteroid injec-
tion] or (2) 0.5 ml Isotonic Saline (0.9%) [Saline injec-
tion]. Injection will be administered into the most
palpably tender point(s) in the region of the lateral epi-
condyle, consistent with previous studies [10,16,19,20].
The syringe will be drawn up and administered with the
participant unable to view its contents to facilitate partic-
ipant blinding. In addition, standardised post-injection
information will be provided verbally and in the form of
a printed pamphlet based on published recommenda-
tions [10,16,21]. Rest from all strenuous activity for 1–2
Process of recruitment, randomization to treatment, treatment provision, and outcomes assessmentFigure 1
Process of recruitment, randomization to treatment, treatment provision, and outcomes assessment.
Telephone Screening Exclusion based 
on eligibility 
criteria
Baseline Outcome Measures
Physical Screening
Informed Consent
Randomisation and 
concealed allocation by 
independent staff
Initial Physiotherapy Session
(n=66)
Follow-up Physiotherapy Sessions x7
(n=66)
Corticosteroid
Injection
(n=33)
Saline
Injection
(n=33)
Corticosteroid
Injection
(n=33)
Saline
Injection
(n=33)
Standardised Advice
Week 4 Outcome Measures
Week 8 Outcome Measures
Week 12 Outcome Measures
Week 26 Outcome Measures
Week 52 Outcome MeasuresPage 3 of 11
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followed by gradual return to normal activities. Partici-
pants will be instructed to avoid aggressive return to activ-
ities even if substantial relief is obtained, to minimise
potential recurrence of their symptoms. All participants
will be warned of normal post-injection responses and to
inform their doctor if there is any suggestion of infection
or other adverse events. All adverse reactions will be man-
aged by a committee chaired by the chief investigator
(BV).
Physiotherapy
A standardised physiotherapy treatment protocol has
been devised based on a recently evaluated program [10].
Eight, 30 minute physiotherapy sessions will be provided
by a post-graduate qualified physiotherapist over an 8
week period. The initial physiotherapy consultation will
be scheduled prior to injection to allow baseline measure-
ment and familiarisation with the program. The primary
rationale for physiotherapy rehabilitation will be relief of
pain, restoration of motor function and facilitation of ten-
don healing [22,23]. A pragmatic multimodal program
comprising education, manipulation and therapeutic
exercise will be used in conjunction with a home exercise
program to address these aims.
Manual Therapy
Specific elbow manipulation techniques known as Mobi-
lisation with Movement (MWM) will be applied, as
described by Vicenzino (2003) [23], based on evidence of
their immediate effects on pain and improved pain-free
grip force; [24,25]. A hydraulic grip dynamometer will be
used to measure baseline pain-free grip force and the
effect of the following glides – lateral elbow glide, pos-
tero-anterior radioulnar glide and de-loading of the com-
mon extensor origin [23]. With the participant's arm
supported in elbow extension and pronation, the thera-
pist will sustain a glide while the participant slowly per-
forms a pain-free grip over approximately 6 seconds. If
substantial improvement in pain-free grip force is noted
with the glide application, the technique may be repeated
6–10 times during a single treatment session. If successful,
self-treatment techniques (Figure 2) will be taught to the
participant using dynamometer feedback in the clinic.
Therapeutic Exercise
A comprehensive exercise program will be used to prima-
rily address motor impairments, but also to address pain
and stimulate tendon remodelling [22]. Three main
groups of exercises will be pragmatically prescribed: (1)
Sensorimotor retraining of gripping and forearm move-
ments (Figure 3) and posture correction will be com-
menced early in the physiotherapy intervention. These
exercises are based on identified motor control deficits
[26-28] and previous 'Occupational training' exercises for
LE [29]. (2) Progressive resistance exercise for the wrist
extensors will be prescribed based on identified strength
deficits in LE [30,31] and proposed effects of exercise on
tendon remodelling [32,33]. Combined concentric and
eccentric exercise will be performed, given insufficient evi-
dence for use of eccentric over concentric modes in LE
[34,35]. Thera-Band™ tubing of varied resistance levels
Table 1: Eligibility criteria
Inclusion criteria
Unilateral elbow pain for longer than six weeks
Pain severity equal or greater than 30 mm on a 100 mm visual analogue scale
Pain over the lateral humeral epicondyle provoked by at least two of: gripping, palpation, stretching of forearm extensor muscles and resisted wrist 
or middle finger extension
Reduced pain-free grip force
Age between 18–70 years
An acceptable understanding of written and spoken English
Willingness to comply with treatment and follow-up assessments
Exclusion criteria
Injection within the preceding 6 months
Course of exercise based physiotherapy program within the preceding 3 months
Concomitant neck or other arm pain that has prevented participation in usual work or recreational activities or necessitated treatment within the 
last 6 months
Evidence of other primary sources of lateral elbow pain including: exacerbation of elbow pain with neck movements or manual examination; pain 
localised over the radiohumeral joint, sensory disturbance in the affected hand
History of fractures within the preceding 10 years, elbow surgery, malignancy, inflammatory or arthritic disorder
Any medical condition which may contraindicate injection or exercise prescription
Pregnant or breastfeedingPage 4 of 11
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sive resistance (Figure 4). Restriction of painful segments
of range will be recommended in early rehabilitation,
with progression to maximal positions of loading involv-
ing elbow extension and forearm pronation as tolerated
[36]. (3) Exercises geared towards general arm strengthen-
ing will be performed with free weights or weight bearing
anti-gravity exercise to address known proximal and bilat-
eral strength deficits found in LE sufferers [31]. Progres-
sion of these exercises to include work or sport-specific
exercises may occur later in rehabilitation.
Physiotherapists will prescribe exercises based on the par-
ticipant's capabilities at any given session to allow for
optimal exercise volume and load setting without exacer-
bating pain [23]. The overriding rule for all exercise is that
pain should not be provoked during or after exercise,
including avoidance of delayed onset muscle soreness.
Exercises will be performed in a slow manner with suffi-
cient rest between sets to allow recovery, and correct form
and posture emphasised throughout. Supervision of the
home program at the commencement of every session
and monitoring of exercise diaries by the treating practi-
tioners will be used to facilitate program adherence and
emphasise the importance of the exercise and self-treat-
ment program.
General information for all participants
All participants will receive standardised advice regarding
activity modification and pain management at the com-
mencement of the study, in the form of a printed pam-
phlet and verbal assessment of their understanding of its
contents. They will be advised that complete rest is detri-
mental to chronic musculoskeletal disorders and activity
that does not cause elbow pain should be encouraged.
Participants will be requested to refrain from seeking not-
per-protocol treatments, however analgesic medications
and elbow braces will be permitted throughout the study
if the participant feels they are needed. Participants will be
questioned at each measurement session regarding usage
of not-per-protocol treatments, including brace use. On
completion of the trial, participants will complete an exit
questionnaire and rate their satisfaction with treat-
ment(s).
Outcome assessment
Participants will be evaluated by a blinded assessor at
baseline, 4, 8, 12, 26 and 52 weeks following randomisa-
tion. The 4 and 8 week time points will be used primarily
to investigate the short term effects of corticosteroid injec-
Retraining of gripping using self-applied lateral (Mobilisation with Movement) glideFigure 2
Retraining of gripping using self-applied lateral 
(Mobilisation with Movement) glide.
Sensorimotor exercise for retraining of isolated wrist exten-sion, with emphasis on avoiding metacarp phalangeal exten-Figure 3
Sensorimotor exercise for retraining of isolated wrist 
extension, with emphasis on avoiding metacar-
pophalangeal extension.
Progressive resistance exercise for wrist extensors using Theraband™Figu  4
Progressive resistance exercise for wrist extensors 
using Theraband™.Page 5 of 11
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iotherapy to injection respectively. The 52 week time
point will provide a primary end point for study of all
long term effects. The data from the other measurement
points (12–52 weeks) will be used to derive indices for
recurrence rates. These time points have been chosen on
the basis of a previous study which noted deterioration in
the corticosteroid injected group during this time period
[10].
Socio-demographic information will be collected at base-
line including age, gender, employment nature, smoking
status, body mass index and physical activity status. Infor-
mation will be sought regarding the nature, duration and
onset of LE symptoms, previous treatment and presence
of concomitant neck or arm pain. The following outcome
measures will be collected at baseline assessment and at
follow-up evaluations as outlined in Table 2.
Primary Outcomes
Global perceived improvement
The participant's self-perceived level of improvement will
be measured with a 6-point Likert scale with categories:
completely recovered, much improved, improved, no
change, worse and much worse [10,20]. The participant
will be asked at each follow-up outcome assessment to
rate the change in their elbow condition since their com-
mencement in the study. A similar retrospective assess-
ment scale has been shown to be more sensitive to change
than serial visual analogue scale measures and more cor-
related with patient's satisfaction with change [37].
Success
Success will be derived from the global perceived
improvement scale as per previous work [10,20]. The cat-
egories 'completely recovered' and 'much improved' will
be dichotomised as 'success', while the other categories
('much worse' to 'improved') will be collapsed to repre-
sent 'no-success'.
Recurrence
Recurrence will primarily be defined as occurring when a
participant rates a success at 4 or 8 weeks and a no-success
beyond 8 weeks on the global perceived improvement
scale [10]. This definition of recurrence which evaluates
the pattern of recurrent events over time has been used in
previous studies of LE [10,20,38]. In addition, partici-
pants will be questioned using a semi-structured interview
at 12, 26 and 52 weeks about their experience of symptom
aggravation and possible reasons for their recurrence. This
data will enable better understanding of recurrences and
best practice measurement of recurrence rates in future
analyses and trials.
Secondary outcome measures
Pain severity
Two visual analogue scales (VAS) anchored by 'no pain' (0
mm) and 'worst imaginable pain' (100 mm) will be used
measure the severity of participants' resting pain and
worst pain experienced during the preceding week. The
VAS is considered the most sensitive of all pain rating
scales and has been specifically evaluated in the LE popu-
lation with high test-retest reliability (r = .89) and moder-
ate correlation with pain-free grip (r = .47) [39].
Patient-rated Tennis Elbow Evaluation
The Patient-rated Tennis Elbow Evaluation (PRTEE) ques-
tionnaire will provide a standardised quantitative assess-
ment of pain and functional disability. It has been shown
to have excellent test-retest reliability (r = .93) and good
correlation with other functional scales including the Dis-
ability of Arm and Shoulder (DASH) questionnaire (r =
.87) in the LE population [40]. Questions are scored on an
11-point Likert scale, with calculation of separate sub-
scales for pain and function and a total score, ranging
from 0 (no pain and no functional disability) to 100
(worst imaginable pain with a very significant functional
disability) [40].
Pain-free grip force
PFG force is well established as a highly reliable (ICC
>.97) and convenient clinical assessment tool, which cor-
relates more strongly with disability and perceived
improvement than maximal grip strength in LE popula-
tions [41-43]. PFG force will be measured using a digital
grip dynamometer with variable handle position (MIE,
Medical Research, UK). The participant will be positioned
in supine with the tested elbow in relaxed extension and
pronation [6]. The participant will be instructed to maxi-
mally squeeze the dynamometer on the unaffected side.
On the affected side, the participant will be asked to grip
Table 2: Outcome measures used at baseline and follow-up 
interviews
Outcome Measures Time Point (weeks)
0 4, 8, 12, 26 & 52
Global Perceived x
Improvement
Resting/Worst Pain (VAS) x x
Pain/Disability (PRTEE) x x
Quality of Life (EuroQol) x x
Anxiety/Depression (HADS) x
Kinesiophobia (Tampa) x
Pain-free Grip Force x x
Pressure Pain Threshold x x
Adverse events x
Willingness-to-pay x
Costs 4 randomly allocated time pointsPage 6 of 11
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but to stop the instant pain is experienced. The average of
three repetitions with 20 second rest intervals will be used
in further analyses.
Pressure pain threshold
Pressure pain threshold (PPT) will be used as quantitative
measure of mechanical hyperalgesia over the lateral epi-
condyle as per previous studies [10,20]. Pressure will be
applied using a digital algometer with a probe size of 1
cm2 (Somedic AB, Farsta, Sweden) at a rate of 40 kPa/s
until the first sensation of pain is recorded. Triplicate
recordings will be taken at each follow-up assessment and
the mean values used for analysis. Measurements will be
performed by the same blinded assessor (BC) as reliability
has been found to be reduced between observers (r = .72–
.98) [41].
The Hospital Anxiety and Depression Scale
The Hospital Anxiety and Depression Scale (HADS) will
be used to identify and quantify the two most common
forms of psychological disturbances – anxiety and depres-
sion [44]. It has been demonstrated to be an appropriate
measure in musculoskeletal pain [45], with evidence of
elevated levels of both anxiety and depression in the LE
population [46]. HADS consists of 14 items which are
independent of somatic symptoms and divided into two
subscales for anxiety and depression. Each item is rated on
a four point scale, with scores of >11 on either subscale
considered to be a significant (probable or definite) case
of psychological morbidity, whereas scores of 8–10 repre-
sent borderline (possible or doubtful) case and 0–7 nor-
mal (non-case) [45].
Tampa Scale for Kinesiophobia
The Tampa Scale for Kinesiophobia (TSK) will be admin-
istered at baseline to assess the degree of kinesiophobia,
also known as fear of movement or (re)injury [47]. While
it has not been studied in the LE population, previous
study of non-traumatic complaints of the neck and arm
found positive associations between kinesophobia and
disability and co-morbidity of musculoskeletal com-
plaints [48]. The adjusted version of this scale (TSK-AV)
will be used due to reported improved factor structure
[48]. Each of the 13 items are scored on a 4-point Likert
scale giving a total score ranging from 13 to 52, with
higher scores indicating greater kinesiophobia.
Health-related quality of life
The EuroQol EQ-5D instrument will be used to measure
health-related quality of life, expressed as utility values
ranging from 0 to 1, where 1 represents perfect health[49].
The utility weights captured by these preferences will ena-
ble the derivation of the Quality Adjusted Life Years
(QALY) for each intervention and will be used in cost-util-
ity analyses. One advantage of using this instrument is
that results of this study can be compared with those of a
previous trial which compared corticosteroid injection,
physiotherapy and a wait and see policy for LE [17].
Costs
Cost data will be collected from a societal perspective,
meaning that an attempt to capture all of the costs, regard-
less of which party or parties incur them, will be made. It
will include a) direct health care costs, such as visits to
doctors, therapists, investigations and prescribed medica-
tion; b) direct non-health care costs, such as costs of over-
the-counter medication, hours of paid and unpaid house-
hold help, transportation and other out-of-pocket
expenses; c) indirect costs, such as absence from work,
housekeeping and other daily activities [50]. Participants
will be asked to recall their out-of-pocket expenses
incurred over the preceding month during a structured tel-
ephone interview by a research assistant not involved in
outcome measurement. The initial interview date will be
randomised by a computer-generated number sequence
to 4, 8 or 12 weeks following commencement of the study
and then subsequent interviews performed at three
monthly intervals. This method of sampling was chosen
to provide sufficient information while minimising the
time commitment required of participants [51]. In addi-
tion, participants will be asked to provide consent for
their Medicare data on in-hospital, out-of-hospital and
pharmaceutical services to be provided by Medicare Aus-
tralia. These data will capture expenditures incurred under
Australia's universal, compulsory health care financing
scheme, Medicare. This includes all expenditures incurred
for general practitioner and specialist services, as well as
pharmaceuticals that are listed on the Pharmaceutical
Benefits Scheme.
Willingness-to-pay
A contingent valuation study will be conducted to elicit an
individual's willingness-to-pay (WTP) for relief of the
symptoms of LE. The contingent valuation approach
results in monetary valuation of the benefits produced by
a health program or health state [52]. An advantage of this
approach is it allows valuation of transitory health states,
which may be important given previous trials suggest con-
siderable temporal variance in the effectiveness of inter-
ventions for LE [10]. Participants will be questioned at
baseline assessment regarding the greatest amount they
are willing to pay, based on the following hypothetical
scenario: "Suppose that your current elbow pain will persist
over the next 12 months if untreated. Imagine that there is a
new treatment that is quick and non-invasive. If it works, it will
provide an immediate and complete cure of your tennis elbow.
However, this treatment only works on 1 in 2 people. The treat-
ment is not covered by Medicare or private insurance." Bias
will be minimised by using both a bidding gamePage 7 of 11
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game approach involves exposing respondents to
repeated bids and identifying the point of indifference
between those bids. In the binary response approach, the
respondent is asked to respond to only one bid. In both
approaches, four bids ($50, $650, $1250 and $1850 in
Australian Dollars) will be randomly allocated to
respondents. The randomisation of bids is a further meas-
ure to reduce the bias that may be generated by the choice
of a starting bid [53]. Specifically, it is known that high
(low) starting bids may lead to higher (lower) WTP valu-
ations. The starting bids will be based on the mean ± 2
standard deviations derived from a similarly designed
pilot study of WTP in LE participants.
Adverse events
All adverse events, defined as any negative or unwanted
reactions to intervention, will be recorded. These will
include pain (lasting longer than 7 days), skin pigmenta-
tion changes, subcutaneous atrophy or any other reported
physical discomfort. As well as the adverse effects commit-
tee (chaired by BV) that will manage adverse reactions at
the time of the adverse reaction, we will administer a
questionnaire at 8 and 52 weeks to record all such patient
identified events. This will capture additional ill effects
not reported at the time of their occurrence. These are
likely to be minor aggravations in symptoms. The ques-
tionnaire will use open-ended questions and will be
placed in a sealed envelope to be opened by a research
assistant not involved in outcome measurement. The
intervention-specific incidence of each adverse event will
be computed.
Randomisation and allocation
Participants will be randomly allocated to groups by con-
cealed allocation. The Queensland Clinical Trials Centre,
an independent off-site body, will be responsible for gen-
erating the computerised randomisation schedule. An
independent research officer will administer the schedule
and perform all communication between participants and
treating practitioners. Randomisation will be stratified
according to baseline pain severity, as it has been found to
be a strong prognostic indicator for LE [54]. The mean
VAS pain score reported in a previous clinical trial (57.5
mm) [10] will be used to classify participants into high
and low baseline pain.
Sample size
The primary aim of this project is to detect a clinically
important difference between injection alone and physio-
therapy plus injection. It is estimated that 120 participants
will be required to detect a 25% difference between phys-
iotherapy and no physiotherapy (α = 0.05, β = 0.2),
assuming a success rate of 27% in the least significant
group. This difference is based on previous work and is
clinically meaningful [20]. An extra 10% will be recruited
to allow for conservative loss to follow-up, bringing the
total participants to 132. The power calculation is based
on previous findings that injection and physiotherapy are
both effective interventions [10,20] and that the combina-
tion of the two will be additive, but not synergistic in
effect.
Planned Data analysis
Clinical Efficacy
All analyses will be conducted on an intention to treat
basis by an investigator who is blind to group allocation.
The outcomes measured at 4, 8, 12, 26 and 52 weeks will
be used to generate efficacy and recurrence indices that
will be analysed using linear mixed and logistic regression
models [10]. Baseline scores for each dependent variable
will be entered as a covariate, relevant participant charac-
teristics entered as a random effect and treatment condi-
tions and time as fixed factors. Variables such as age,
gender, duration of condition, nature of employment will
be included as covariates in the analysis, if found to signif-
icantly influence outcomes over time. Regression diagnos-
tics will be used to check for normality of the measures
and homogeneity of variance where appropriate. Alpha
will be set at 0.01 to compensate for the possible increase
in type I error rates that may result from multiple testing.
The dichotomous measures of success and recurrence will
be analysed using relative risk, and numbers needed to
treat in order to provide a meaningful indicator of treat-
ment efficacy to practitioners.
Health Economics
Participants' utility weights will be derived from EQ-5D
responses. These QALY computations will be used along
with cost data to enable cost-effectiveness analyses to be
undertaken. As Australian weights for the EQ-5D are cur-
rently unavailable, we propose to use the available scoring
algorithms for the UK and NZ to compute QALY esti-
mates, with the variation between results forming the
basis for a cost-per-QALY sensitivity analysis [49]. Captur-
ing participants' WTP for treatment will provide an alter-
native measure of the marginal benefits associated with
intervention and will be used in cost-benefit analyses.
Care will be taken to avoid double counting the benefits
estimated via the contingent valuation approach. The dis-
tribution of the WTP data will be analysed to examine not
only the distribution of the responses, but also the effect
of the starting bid and of respondent income on WTP.
Modern statistical procedures, such as bootstrapping, will
be used to assess the uncertainty surrounding costs and
effects.
Discussion
The basis for a combined approach of injection and phys-
iotherapy is twofold. First there is the evidence of a rapidPage 8 of 11
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BMC Musculoskeletal Disorders 2009, 10:76 http://www.biomedcentral.com/1471-2474/10/76improvement (3 weeks) following corticosteroid injec-
tions [10,20] that is followed by higher recurrence rates
and a relative delay in recuperation in the long term (> 6
weeks) [10,11]. Second, is the comparable effect of physi-
otherapy to corticosteroid injections at 6 weeks and the
relative superiority of physiotherapy, in terms of lower
recurrence rates, after that point. In addition, there is evi-
dence of a beneficial effect of preventing chronicity fol-
lowing an eight week exercise program in chronic LE
patients, the majority of whom had not responded to
local corticosteroid injection [29,55]. Improved forearm
strength has been reasoned to protect against chronicity
and recurrence [29,56].
Use of a placebo intervention coupled with blinding is
intended to prevent bias resulting from non-specific
effects associated with those receiving the intervention
(placebo effects) [57]. Local anaesthetic injection has
been utilised as a placebo comparison [58,59], however
this medication may be in part responsible for short term
analgesic effects. Normal saline, in comparison, is consid-
ered to have no, or very little, therapeutic effect. In this
study, a small volume (0.5 ml) of normal saline will be
injected to minimise potential mechanical effects of a vol-
ume of fluid on local structures.
This study adheres to the CONSORT statement for ran-
domised controlled trials [57,60]. Randomisation of par-
ticipants by concealed allocation will be performed, as
this feature is known to minimise bias [61]. Blinding strat-
egies will be employed such that the participant and asses-
sor are blind to the injection content (double blinding).
The nature of the physiotherapy program means that
blinding of patients and practitioners is not possible,
however the assessor will be blinded to the allocation of
physiotherapy (single blinding). Success in blinding of
injection content will be evaluated at 8 and 52 weeks by
both participant and assessor. This trial uses outcome
measures that have established reliability and validity to
enhance the quality of the outcomes and facilitate com-
parison with studies of LE and other musculoskeletal con-
ditions. The statistical analysis will be conducted on an
intention-to-treat basis. The influence of group allocation
on the utilisation of not-per-protocol treatments will also
be evaluated, in order to fully describe patient behaviours
in a realistic context in which there are more than the
study's interventions available. This study has been
designed to optimise applicability to the clinical setting so
that practitioners will be able to use the data in their day-
to-day management of LE. For example, participants will
be included on explicit clinical diagnostic criteria, inter-
ventions will be delivered in primary care settings and
many of the outcome measures can be readily used in
clinical practice.
It is becoming increasingly important to determine the
costs relative to the benefits, measured either in monetary
values or gains in health-related quality of life, of the com-
bined injection and physiotherapy approach. The inclu-
sion of an economic evaluation in this trial provides a
basis for considering the economic arguments for invest-
ments in the interventions of interest here, and their com-
parison to other health sector interventions. The
measurement of costs from a societal perspective encom-
passes those costs incurred by the patient and his/her fam-
ily, private and public sector payments and productivity
losses [53]. Evaluation of the value of improved health
will be measured using physical measures of health-
related quality of life (e.g., QALYs) and WTP measures.
The range of measures that will be used in this study pro-
vides us with considerable flexibility to examine the eco-
nomic impacts of the interventions.
Conclusion
An effective treatment strategy that provides rapid allevia-
tion of LE and that is maintained in the long term is
needed. This project is designed to provide high quality
evidence evaluating the ability of physiotherapy to aug-
ment corticosteroid injection in the treatment of LE. It will
do this by studying the clinical notion that the combined
approach is preferred to that of injection alone. Addition-
ally, it will provide further insight into the therapeutic
basis of corticosteroid injection by comparison to a pla-
cebo injection.
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